Citius Pharmaceuticals
CTXR
10 hedge funds and large institutions have $613K invested in Citius Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
23% more capital invested
Capital invested by funds: $499K → $613K (+$114K)
0.04% more ownership
Funds ownership: 0.08% → 0.11% (+0.04%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
9% less funds holding
Funds holding: 11 → 10 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$390K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.16K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$2.71K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$38K |
| 2 |
Morgan Stanley
New York
|
-$29K |
| 3 |
Renaissance Technologies
New York
|
-$23K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $444K | +$390K | +13,687 | +308% |
|
|
BAAM
2
Baker Avenue Asset Management
San Francisco,
California
| $83K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $50K | -$23K | -808 | -28% |
|
4
Dimensional Fund Advisors
Austin,
Texas
| $14K | – | – | – |
|
|
RJA
5
Raymond James & Associates
St Petersburg,
Florida
| $12K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $4K | +$4.16K | +146 | New |
|
7
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
|
8
Bank of America
Charlotte,
North Carolina
| $2K | +$2.71K | +95 | New |
|
|
HCM
9
Hilton Capital Management
Garden City,
New York
| $1K | – | – | – |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$38K | -1,063 | Closed |
|
|
12
Morgan Stanley
New York
| – | -$29K | -840 | Closed |
|
|
13
Acadian Asset Management
Boston,
Massachusetts
| – | -$10K | -289 | Closed |
|
CTXR Hedge Fund Activity: Q2 2019 in Review
10 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2019, worth a combined $613K — up 23% from $499K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CTXR and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, adding an estimated $390K. The largest seller was Citadel Advisors, exiting entirely with an estimated $38K sold.
- 10 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2019, down from 11 in Q1 2019.
- Funds reported $613K of Citius Pharmaceuticals stock for Q2 2019, up 23% quarter-over-quarter.
- 2 funds opened new Citius Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of -1 holder.
- The largest Citius Pharmaceuticals buyer in Q2 2019 was Vanguard Group, an estimated $390K added.
- The largest Citius Pharmaceuticals seller in Q2 2019 was Citadel Advisors, an estimated $38K sold.
Based on aggregated 13F filings for Q2 2019.